11.01.2013 Views

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

The dal-HEART Program:<br />

Dalcetrapib HDL Evaluation, Atherosclerosis,<br />

and Reverse Cholesterol Transport<br />

dal-VESSEL<br />

450 patients with<br />

CHD or CHD risk<br />

equivalent<br />

To evaluate the<br />

effect of<br />

dalcetrapib on<br />

endothelial<br />

function and BP,<br />

measured by<br />

FMD and ABPM<br />

dal-PLAQuE<br />

130 patients with<br />

CHD<br />

To evaluate the<br />

effect<br />

of dalcetrapib<br />

on<br />

inflammation,<br />

plaque<br />

size, and burden,<br />

measured by<br />

PET/CT and MRI<br />

scans<br />

dal-PLAQUE 2<br />

900 patients<br />

with CAD<br />

To evaluate the<br />

effect of<br />

dalcetrapib on<br />

CVD<br />

progression,<br />

assessed by<br />

IVUS<br />

and carotid Bmode<br />

ultrasound<br />

dal- ACUTE<br />

300 patients<br />

with ACS<br />

To evaluate<br />

the safety and<br />

efficacy of<br />

dalcetrapib in<br />

patients<br />

hospitalized for<br />

ACS. Treatment<br />

initiated within<br />

1 week a nd<br />

last for 20<br />

weeks<br />

ACS=acute coronary syndrome; FMD=flow-mediated dilation; ABPM=ambulatory blood pressure monitoring;<br />

CAD=coronary artery disease; IVUS=intravascular ultrasound; PET=positron emission tomography;<br />

CT=computed tomography; MRI=magnetic resonance<br />

Schwartz GG, et al. Amer. Heart J. 2009;158:896-901<br />

55

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!